Author's response to reviews

Title: Quantification of Cancer Risk in Glomerulonephritis

Authors:

James Heaf (heaf@DADLNET.DK)
Alastair Hansen (alastair.hansen@regionh.dk)
Gunnar Laier (guhl@regionssjaelland.dk)

Version: 2 Date: 10 Jan 2018

Author’s response to reviews:

Response to editors comments

1. We note that the current submission contains some textual overlap with other previously published works, in particular:

"LONG-TERM OUTCOME IN 145 PATIENTS WITH ASSUMED BENIGN IGA NEPHROPATHY"

(2017) Nephrology Dialysis Transplantation,

https://doi.org/10.1093/ndt/gfx129.TO014

This overlap exists in the Abstract section.

While we understand that you may wish to express some of the same ideas contained in these publications, please be aware that we cannot condone the use of text from previously published work.

Please re-phrase these sections to minimise overlap.

Response: We have discussed this per e-mail. The search engine has erroneously attributed the text to a wrong abstract. This is a common error in ERA-EDTA congress reports which attribute all abstracts to the first presentation in each session. The text contains an oral presentation of our results at the Madrid congress. I have therefore chosen to leave the text unaltered.

2. Please remove the statement 'All authors have reviewed and approved this paper for publication' from the section 'Consent for Publication', as this section does not apply to authors.

Response: this has been done
3. We notice that there are two 'Availability of Data and Materials' sections in the Declarations. Please merge these two sections into one, including both statements.

Response: This has been done.

4. Please include the email addresses for all authors on the title page. The corresponding author should still be indicated.

Response: This has been done.

5. Please change the heading 'Introduction' to 'Background'.

Response: This has been done.

6. Please remove the duplicate manuscript with tracking changes, as at this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

This has been done.

------

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Nephrology.

Once you have made the necessary corrections, please submit a revised manuscript online at:

http://bnep.edmgr.com/

If you have forgotten your username or password please use the "Send Login Details" link to get your login information. For security reasons, your password will be reset.

We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

Please also ensure that your revised manuscript conforms to the journal style, which can be found in the Instructions for Authors on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 22 Dec 2017.
Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies. To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - http://www.biomedcentral.com/about/editorialpolicies#authorship. Please note that incomplete forms will be rejected. Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Stephanie Martin on behalf of

Louise Symmons

BMC Nephrology

https://bmcnephrol.biomedcentral.com/

Editor Comments:

I would congratulate the author and co-authors in their efforts with the revised manuscript. It is an important addition to the evidence base that associates glomerular disease with incident and prevalent cancer in a population-based study.

The only additional point that I would make is that the number of Tables (n=7) appear excessive and some may be considered for inclusion as supplementary files in online format.

Response: We do apologize. We feel that all the tables are important, containing either important results, or data to help the physicians in treating patients. We wish to keep them in the paper. If this is unacceptable, please move the necessary tables to the Supplementary files section.